Five-Year Peak Sales Forecast of Newly Reimbursed Drugs in Japan Surges to $34bn
March 11, 2015.
The overall output of the Japanese drug industry measured by expected peak sales potential of newly National Health Insurance (NHI)-reimbursed drugs surged to $34 billion between 2010-2014, up from $16.9 billion during 2005-2009, according to Evaluate’s new report, Japan Sales, Volume, Pricing 2015. Highlights of the report include
- Peak sales forecast of newly reimbursed drugs surged to $34 billion between 2010-14 compared to $16.9 billion during 2005-09.
- Quantity of reimbursed drugs increased 8 percent to 64 in 2014 vs. 2013; peak sales forecasts increased 19 percent in 2014 to $6.3 billion.
- The median reimbursed price for Japanese drugs between 2005-14 was 40 percent lower than the US; 20 percent lower than Germany.
- New endocrine drugs have the highest peak sales potential with central nervous system drugs coming in second.
- Median annual cost of new drugs jumped to $837 (¥95k) in 2010-14 from $697 (¥82k) in 2005-09.
The full version of the report can be downloaded at
www.evaluategroup.com/JapanSalesVolumePricing2015
.
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
